Anti-Galectin-9 Antibody for Selective Treg Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing therapeutic strategies for inhibiting the suppressor activity of regulatory T lymphocytes lack specificity, leading to unintended suppression of effector T lymphocytes, which are crucial for anti-tumoral responses.
Innovation Solution
Development of an antibody specifically targeting Galectin-9, expressed by regulatory T lymphocytes but not effector T lymphocytes, to inhibit the suppressor activity of regulatory T lymphocytes without affecting effector T lymphocytes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapeutic strategies target surface molecules expressed by regulatory T lymphocytes (such as CD25, GITR, CTLA4), then the suppressor activity of regulatory T lymphocytes is inhibited, but effector T lymphocytes are also suppressed because these surface molecules are also expressed by effector T lymphocytes
Solution Approach 1:
The patent applies local quality by targeting Galectin-9, a molecule specifically overexpressed by regulatory T lymphocytes during activation, while being absent or minimally expressed by effector T lymphocytes. This selective targeting ensures that the inhibitory effect is localized to regulatory T lymphocytes without affecting effector T lymphocytes, thereby resolving the contradiction between achieving reliable inhibition and avoiding harmful side effects
Solution Approach 2:
The patent segments the T lymphocyte population by identifying a specific molecular marker (Galectin-9) that distinguishes regulatory T lymphocytes from effector T lymphocytes. By targeting this segmented marker, the therapy can selectively inhibit regulatory T lymphocytes while preserving effector T lymphocyte function, thus achieving both high reliability and avoiding harmful suppression
2Reliability
If monoclonal antibodies are used to target surface molecules on regulatory T lymphocytes, then the suppressor activity is reduced, but the complexity of the therapeutic strategy increases due to the need for highly specific targeting
Solution Approach 1:
The patent extracts the key distinguishing feature (Galectin-9 expression) from the complex landscape of T lymphocyte surface molecules. By focusing on this single extracted marker that is specifically overexpressed by activated regulatory T lymphocytes, the therapy simplifies the targeting strategy while maintaining high reliability, avoiding the need to simultaneously target multiple molecules
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody effectively inhibits the suppressor activity of regulatory T lymphocytes, enhancing anti-tumoral immune responses by maintaining the functionality of effector T lymphocytes.
Implementation Method 1
an antibody directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory T lymphocytes
Data Source
AI summary
The disclosure relates to an antibody which is directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory T lymphocytes, and also to the use of this antibody for the treatment of diseases associated with the suppressor activity of regulatory T lymphocytes, in particular the treatment of cancer.